4 December 2023 - Changes to the Dental and Pharmaceutical Benefits Agency's regulations and general advice on the pricing of ...
18 October 2023 - TLV has prepared a health economic assessment for the regions for the medicine Beyfortus (nirsevimab). ...
13 October 2023 - TLV has produced a health economic assessment of Enhertu (trastuzumab deruxtecan) for the regions. ...
2 October 2023 - The Swedish Dental and Medicines Benefits Agency, TLV, today submits a report to the government on how ...
9 October 2023 - The European Commission's proposal for a new regulation and directive has a decisive impact on the quality ...
29 September 2023 - Pricing and subsidy methods and processes need to be developed to address the challenges that arise when ...
4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...
19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...
16 June 2023 - There are more and more new drugs, and more people are receiving treatment for their illnesses. At ...
12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan). ...
12 June 2023 - The Supreme Administrative Court decided on 3 May not to grant a review permit for Mayzent. ...
11 May 2023 - On 10 May 2023, the Nordic HTA collaboration FINOSE was extended for another three years and the ...
12 April 2023 - TLV has decided to increase ceiling prices in certain package size groups. The decision to raise ceiling ...
4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...
31 March 2023 - The TLV has submitted an interim report to the government for the task of proposing how ...